The state of the art of bispecific antibodies for treating human malignancies

Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuhang, Chen, Kun, Lei, Qi, Ma, Peiwen, Yuan, Andy Qingan, Zhao, Yong, Jiang, Youwei, Fang, Hong, Xing, Shujun, Fang, Yuan, Jiang, Ning, Miao, Huilei, Zhang, Minghui, Sun, Shujun, Yu, Zicheng, Tao, Wei, Zhu, Qi, Nie, Yingjie, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422067/
https://www.ncbi.nlm.nih.gov/pubmed/34431224
http://dx.doi.org/10.15252/emmm.202114291
_version_ 1783749211560345600
author Wang, Shuhang
Chen, Kun
Lei, Qi
Ma, Peiwen
Yuan, Andy Qingan
Zhao, Yong
Jiang, Youwei
Fang, Hong
Xing, Shujun
Fang, Yuan
Jiang, Ning
Miao, Huilei
Zhang, Minghui
Sun, Shujun
Yu, Zicheng
Tao, Wei
Zhu, Qi
Nie, Yingjie
Li, Ning
author_facet Wang, Shuhang
Chen, Kun
Lei, Qi
Ma, Peiwen
Yuan, Andy Qingan
Zhao, Yong
Jiang, Youwei
Fang, Hong
Xing, Shujun
Fang, Yuan
Jiang, Ning
Miao, Huilei
Zhang, Minghui
Sun, Shujun
Yu, Zicheng
Tao, Wei
Zhu, Qi
Nie, Yingjie
Li, Ning
author_sort Wang, Shuhang
collection PubMed
description Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we provide an overview of various types of bsAbs in clinical studies and discuss their targets, safety profiles, and efficacy. We also highlight the current challenges, potential solutions, and future directions of bsAb development for cancer treatment.
format Online
Article
Text
id pubmed-8422067
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84220672021-09-10 The state of the art of bispecific antibodies for treating human malignancies Wang, Shuhang Chen, Kun Lei, Qi Ma, Peiwen Yuan, Andy Qingan Zhao, Yong Jiang, Youwei Fang, Hong Xing, Shujun Fang, Yuan Jiang, Ning Miao, Huilei Zhang, Minghui Sun, Shujun Yu, Zicheng Tao, Wei Zhu, Qi Nie, Yingjie Li, Ning EMBO Mol Med Reviews Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we provide an overview of various types of bsAbs in clinical studies and discuss their targets, safety profiles, and efficacy. We also highlight the current challenges, potential solutions, and future directions of bsAb development for cancer treatment. John Wiley and Sons Inc. 2021-08-24 2021-09-07 /pmc/articles/PMC8422067/ /pubmed/34431224 http://dx.doi.org/10.15252/emmm.202114291 Text en © 2021 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Wang, Shuhang
Chen, Kun
Lei, Qi
Ma, Peiwen
Yuan, Andy Qingan
Zhao, Yong
Jiang, Youwei
Fang, Hong
Xing, Shujun
Fang, Yuan
Jiang, Ning
Miao, Huilei
Zhang, Minghui
Sun, Shujun
Yu, Zicheng
Tao, Wei
Zhu, Qi
Nie, Yingjie
Li, Ning
The state of the art of bispecific antibodies for treating human malignancies
title The state of the art of bispecific antibodies for treating human malignancies
title_full The state of the art of bispecific antibodies for treating human malignancies
title_fullStr The state of the art of bispecific antibodies for treating human malignancies
title_full_unstemmed The state of the art of bispecific antibodies for treating human malignancies
title_short The state of the art of bispecific antibodies for treating human malignancies
title_sort state of the art of bispecific antibodies for treating human malignancies
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422067/
https://www.ncbi.nlm.nih.gov/pubmed/34431224
http://dx.doi.org/10.15252/emmm.202114291
work_keys_str_mv AT wangshuhang thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT chenkun thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT leiqi thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT mapeiwen thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT yuanandyqingan thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT zhaoyong thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT jiangyouwei thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT fanghong thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT xingshujun thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT fangyuan thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT jiangning thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT miaohuilei thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT zhangminghui thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT sunshujun thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT yuzicheng thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT taowei thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT zhuqi thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT nieyingjie thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT lining thestateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT wangshuhang stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT chenkun stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT leiqi stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT mapeiwen stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT yuanandyqingan stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT zhaoyong stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT jiangyouwei stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT fanghong stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT xingshujun stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT fangyuan stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT jiangning stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT miaohuilei stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT zhangminghui stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT sunshujun stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT yuzicheng stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT taowei stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT zhuqi stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT nieyingjie stateoftheartofbispecificantibodiesfortreatinghumanmalignancies
AT lining stateoftheartofbispecificantibodiesfortreatinghumanmalignancies

Ejemplares similares